Editorial Advisory Board
Editorial Advisory Board

DDW is proud to have some of the world's leading experts in the field of Pharmaceutical and Biotech R&D on its board.

Dr. Roger Brimblecombe
Drug Discovery World
is under the editorial guidance of Dr. Roger Brimblecombe (ex Chairman Smith Kline & French Research). Dr Brimblecombe brings a wealth of experience to Drug Discovery World.

He is the former Chairman of Smith Kline & French Research Ltd and held various Vice-Presidential posts within the SmithKline Corporation. Subsequently he has been Chairman of Vanguard Medica Ltd, Core Group plc, Oxford Asymmetry Ltd, Oxxon Pharmaccines Ltd, DanioLabs Ltd, MVM Ltd and M&E Biotech A/S (Denmark). He has also served as a Non Executive Director of a number of biotech companies in the US, Europe, Singapore and Australia.

He recently retired from the post of Executive Chairman and CEO of pSivida Ltd. He retains Non Executive Directorships of Vertex Pharmaceuticals Inc (US), Vertex Pharmaceuticals (Europe) Ltd and Tissue Science Laboratories plc and is a Partner in MVM Life Science Partners LLP. He is also a Non Executive Director of the Gloucestershire Partnership NHS Trust.

He has been Chairman of the Society of Pharmaceutical Medicine and of the Scientific Committee of the Association of British Pharmaceutical Industry and also a member of the Councils of the Royal College of Pathologists and the Institute of Biology.

Other Members of the Advisory Panel:

Dr Steve Arlington
Dr Arlington has more than 10 years' experience in pharmaceutical research and development both as a project team leader and research group manager resulting in the development and launch of a number of world class drugs and diagnostic tests. As a partner of PricewaterhouseCoopers and global leader of the Pharma R&D practice, with total responsibility for the European pharmaceutical business, Dr Arlington has acquired a further 15 years experience working extensively with company boards and senior management in the areas of R&D and e-Business strategy.

Dr Nigel Brown
Dr. Brown received his bachelor's degree (chemistry) and his doctorate (natural products metabolism) from the University of Oxford, England, funded by the U.S. National Institutes of Health. He was subsequently awarded a Nestlé postdoctoral fellowship at Massachusetts Institute of Technology, where his research focused on the cancer-forming potential of several common food products. He joined the Department of Drug Metabolism and Pharmacokinectics at The Upjohn Company in 1991, where he supported drug metabolism research and first-in-human clinical trials.

In 1993 Dr Brown moved to SmithKline Beecham R&D where he played a key role in introducing LC/MS/MS as the principal analytical tool for metabolic and pharmacokinetic assessment. In 1997 Dr. Brown joined Phoenix International Life Sciences, a high-growth CRO, in a general management capacity overseeing preclinical operations. Following the acquisition of Phoenix International by MDS, Dr. Brown ran MDS Pharma Service's global preclinical enterprise.

After receiving his MBA, Dr. Brown transitioned his focus to Corporate Strategy and M&A within the CRO sector. He has worked for Covance since June 2006 as head of corporate development and strategy. Dr. Brown sits on the management team of Covance Inc., serves on the boards of several healthcare companies, and has published broadly in scientific and business journals. Dr Brown is based in Princeton, New Jersey.